2022-12-31-accounts - The British Gynaecological Cancer Society

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

						2022	2021
				Unrestricted	Restricted	Total	Total
				fund	fund	funds	funds
			Notes	6	f		f
INCOME	AND ENDOWMENTS FROM
Donations	and legacies			383		383
Charitable	activities		3
To advance	the science	and art ofgynaecological
oncology for the benefit of the public				316,542		316,542	218,991
Investment	income			189		189	14
Other income							553
Total				317,114		317,114	219,558
EXPENDITURE ON
Charitable	activities		4
Toadvance	the science	and art ofgynaecological
oncology for the benefit ofthe public				250,680		250,680	88,013
NET INCOME				66,434		66,434	131,545
RECONCILIATION		OFFUNDS
Total funds	brought forward			573,011		573,0]I	441,466
TOTAL FUNDS CARRIED FORWARD				639,445		639,445	573,011

				2022	2021
		Unrestricted	Restricted	Total	Total
		fund	fimd	tbnds	funds
	Notes		6
CURRENT ASSETS
Debtors		85,306		85406	107,379
Cash at bank		566,114		566,114	476,082
		651,420		651,420	583,461
CREDITORS
Amounts falling due within one year	10	(11&975)		(11&975)	(10,450)
NET CURRENT ASSETS		639&445		639&445	573,011
TOTAL ASSETSLESSCURRENT
LIABILITIES		639,445		639&445	573,011
NET ASSETS		639,445		639,445	573,011
FUNDS
Unrestricted funds				639&445	573,011
TOTALFUNDS				639,445	573,011

	INCOME	FR	OM CH	ARITABLE ACTIVIT	IES
						2022	2021
				Activity
				To advance the	science and art of
				gynaecological	oncology for the benefit of
	Sponsorships			the public		120,500	88,400
				To advance the	science and art of
				gynaecological	oncology for the benefit of
	Delegate fees			the public		143,030	81,285
				To advance the	science and art of
				gynaecological	oncology for the benefit of
	Subscriptions			the public		53,012	49,306
						316,542	218,991
4.	CHARITABLE ACTIVITIES COSTS
						Support
					Direct	costs (see
					Costs	note 5)	Totals
					8
	To advance	the	science	and art of
	gynaecological		oncology for the benefit
	ofthe public				222,943	27,737	250,680
5.	SUPPORT	COSTS
						Governance
					Management	costs	Totals
							f
	To advance the		science	and art of
	gynaecological		oncology for the benefit of
	the public				23,199	4,538	27,737
	INDEPENDENT EXAMINER'S FEES
						2022f	2021 6
	Independent	examiner's		fees		2,200	2,079

	Trustees' expenses
				2022	2021
	Trustees' expenses			2,33$
$.	COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES
			Unrestricted	Restricted	Total
			fund	fund	funds
			f		K
	INCOME AND ENDOWMENTS FROM
	Charitable activities
	To advance the science	and srt of
	gynaecological oncology for the benefit ofthe
	public		218,991		218,991
	Investment income		14		14
	Other income		553		553
	Total		219,558		219,558
	EXPENDITURE ON
	Charitable activities
	To advance the science	and art of
	gynaecologicsl oncology for the benefit ofthe
	public		88,013		88,013
	NET INCOME		131,545		131,545
	RECONCILIATION	OF FUNDS
	Total funds brought forward		441,466		441,466
	TOTAL FUNDS CARRIED FORWARD		573,011		573,011

9.	DEBTORS:	DEBTORS:	AMOUNTS FALLING DUE WITHIN ONE YEAR	AMOUNTS FALLING DUE WITHIN ONE YEAR	AMOUNTS FALLING DUE WITHIN ONE YEAR
							2022	2021
	Other debtors						61,308	105,032
	VAT						8,570
	Prepayments						15,428	2,347
							85@06	107,379
10.	CREDITORS:			AMOUNTS FALLING DUE WITHIN ONE YEAR
							2022	2021f
	VAT							7,260
	Other creditors						7,276	1,191
	Accruals	and	deferred income				2&500
	Accrued	expenses					2,199	1,999
							11)975	10,450
11.	MOVEMENT			IN FUNDS
							Net
							movement	At
					At	1.1.22	in funds	31.12.22
	Unrestricted		funds
	General	fund			573,011		66,434	639&445
	TOTAL	FUNDS			573,011		66)434	639,445
	Net movement		in funds, included		in the above are as follows:
					Incoming		Resources	Movement
					resources		expended	in funds
						f.
	Unrestricted		funds
	General	fund			317,114		(250,680)	66,434
	TOTAL	FUNDS			317,114		(250,680)	66,434